Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This study developed a niosomal delivery system loaded with tretinoin and bicalutamide, optimized for follicular targeting in acne management, showing promising accumulation in hair follicles in animal models.

This abstract discusses the efficacy of spironolactone, cyproterone acetate, and flutamide in treating female pattern hair loss, noting that flutamide use requires caution due to potential liver toxicity, especially at high doses.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

This article notes that low-dose systemic minoxidil combined with antiandrogen therapy is effective for treating female pattern hair loss, though hypertrichosis can occur in a significant percentage of patients.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

This study by Moussa et al. reported that bicalutamide may help reduce minoxidil-induced hypertrichosis in women with female pattern hair loss.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.

This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.

This case series evaluated the use of oral bicalutamide with low-dose oral minoxidil in women with female pattern hair loss who didn't respond to minoxidil alone, finding that 96.6% showed improvement after six months without adverse effects.

This retrospective cohort study found that both spironolactone and bicalutamide significantly improved Sinclair grade in women with female pattern hair loss over 24 months, but spironolactone, especially at doses above 100 mg/day, resulted in greater efficacy, required less monitoring, and maintained comparable safety.

In this case report, a 45-year-old man with treatment-resistant androgenetic alopecia experienced hair regrowth during oral bicalutamide treatment but also suffered adverse effects leading to discontinuation, highlighting the need for further studies on the safety and role of androgen receptor blockade in hair loss.

In this randomized trial, bicalutamide was found to improve hair count and shaft diameter more than spironolactone in women with Female Pattern Hair Loss over 24 weeks, although no significant differences were observed in clinical endpoints between the two treatments.

Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.

Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

Bicalutamide shows promise for treating female hair loss.

This study suggests bicalutamide may be effective in reducing hair loss severity in female pattern hair loss, particularly when other antiandrogen therapies are less effective due to hyperandrogenic conditions.

Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

In this study, researchers found that bicalutamide was more effective and had a better safety profile than spironolactone for treating female-pattern hair loss in women aged 18 to 50, based on the Sinclair scale and photographic assessments after 24 weeks of treatment.